Market cap
₹4,33,848 Cr
Recently Viewed
Clear AllNSE: SUNPHARMA | BSE: 524715
₹1,808.30
₹29.60
(1.66%)
As on 30-Apr-2026IST
Market cap
₹4,33,848 Cr
Revenue (TTM)
₹56,809 Cr
P/E Ratio
39.7
P/B Ratio
5.3
Div. Yield
0.9 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹10,915 Cr
ROE
16.2 %
ROCE
19.9 %
Industry P/E
29.38
EV/EBITDA
21.7
Debt to Equity
0
Book Value
₹338.5
EPS
₹50.6
Face value
1
Shares outstanding
2,399,334,970
CFO
₹72,747.75 Cr
EBITDA
₹94,395.47 Cr
Net Profit
₹58,337.09 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
| 5.2 | 0.8 | 13.8 | 0.2 | 22.3 | 22.9 | 8.3 |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
| -9.0 | 49.7 | 25.8 | 18.4 | 41.8 | 36.4 | -0.2 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
|
1,808.3 | 4,33,847.8 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 39.7 | 5.3 |
| 5,400.0 | 64,613.5 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27.2 | 4.6 | |
| 1,389.5 | 80,705.3 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 23.1 | 2.2 | |
| 359.7 | 58,279.7 | 16,827.4 | 629.6 | 9.6 | -0.1 | 96.5 | 1.5 | |
| 1,309.6 | 1,05,811.5 | 28,351.1 | 4,544.7 | 18.8 | 14.8 | 23.3 | 3.1 | |
| 1,322.9 | 1,10,420.9 | 34,682.2 | 5,508.7 | 17.6 | 16 | 19.8 | 3.0 | |
| 2,305.2 | 1,05,320.4 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.7 | 5.1 | |
| 2,246.7 | 92,744.0 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 52.1 | 5.9 | |
| 4,185.1 | 1,41,859.4 | 12,742.0 | 2,272.0 | 26.3 | 28.8 | 62.4 | 15.6 | |
| 891.9 | 89,720.9 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.2 | 3.4 |
A hunt for quality large caps available cheap
3 min read•By Jugal Harpalani
2 min read•By Value Research
6 min read•By Kumar Shankar Roy
1 min read•By Yash Rohra
2 min read•By Mohammed Ekramul Haque
Who wins in India: Value or Growth?
3 min read•By Kumar Shankar Roy
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company... offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India. Read more
Incorporated
1993
Chairman
Dilip S Shanghvi
Managing Director
Kirti Ganorkar
Group
Sun Pharma
Headquarters
Vadodara, Gujarat
Website
Looking for more details about Sun Pharmaceutical Industries Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsIncorporation Of A Subsidiary Company
24-Apr-2026Rumour verification - Regulation 30(11)
10-Apr-2026No News & Announcements are available.
The share price of Sun Pharmaceutical Industries Ltd is ₹1,808.30 (NSE) and ₹1,808.20 (BSE) as of 30-Apr-2026 IST. Sun Pharmaceutical Industries Ltd has given a return of 22.34% in the last 3 years.
The P/E ratio of Sun Pharmaceutical Industries Ltd is 39.75 times as on 30-Apr-2026, a 35 premium to its peers’ median range of 29.38 times.
The P/B ratio of Sun Pharmaceutical Industries Ltd is 5.34 times as on 30-Apr-2026, a 16 premium to its peers’ median range of 4.62 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
38.10
|
5.77
|
|
2024
|
40.60
|
6.11
|
|
2023
|
27.84
|
4.21
|
|
2022
|
67.07
|
4.57
|
|
2021
|
49.38
|
3.09
|
The 52-week high and low of Sun Pharmaceutical Industries Ltd are Rs 1,851.20 and Rs 1,548.00 as of 02-May-2026.
Sun Pharmaceutical Industries Ltd has a market capitalisation of ₹ 4,33,848 Cr as on 30-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Sun Pharmaceutical Industries Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.